ClinicalTrials.gg

Program

prizloncabtagene autoleucel

Also written as “Prizloncabtagene Autoleucel” and “Prizloncabtagene autoleucel”.

Its studies are mostly in Lymphoma, Large B-Cell, Diffuse, led by AbelZeta.

Furthest: phase 2, since Mar 24, 20232 company-led studies, 2 open or runningNext primary completion: Mar 31, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AbelZeta22 open or runningphase 2since Mar 24, 2023Mar 24, 2023Mar 31, 2027phase 2 · NCT05800977

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 24, 2023First study: phase 2 study in RecurrenceFirst studyNCT05800977 · 112 planned · China
  2. Oct 6, 2026Phase 2 study in Lymphoma, Large B-Cell, DiffuseNCT07875413 · 55 planned · United States

Ahead

  1. Mar 31, 2027Primary completion: phase 2 study in RecurrenceNCT05800977
  2. Jun 2029Primary completion: phase 2 study in Lymphoma, Large B-Cell, DiffuseNCT07875413

TargetBeta

CD19 →MS4A1 →read by rule
“A preparation of autologous T-lymphocytes engineered to express a second-generation chimeric antigen receptor (CAR) specific for the two tumor-associated antigens (TAAs) cluster of differentiation 19 (CD19) and CD20, ”NCIt, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
rondecabtagene autoleucelrulelyell-immunopharma-incphase 32
zamtocabtagene autoleucelrulemiltenyi-biomedicine-gmbhphase 28
Autologous Anti-CD19/CD20 CAR-T Cells KITE-363ruleGilead Sciencesphase 23
GSK5926371GlaxoSmithKlinephase 22
Allogeneic Anti-CD19/CD20 CAR T-cells AVC-203ruleavencell-therapeutics-incphase 21
CT204V-CD19 × CD20ruleAstraZenecaphase 21
HB2198rulehinge-biophase 11

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07875413Lymphoma, Large B-Cell, Diffuse · United States2Not yet recruitingJun 202955
NCT05800977Recurrence · China2RecruitingMar 31, 2027112

How it is read

Names in the registry

  • “Prizloncabtagene Autoleucel”, 1 entry
  • “Prizloncabtagene autoleucel”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.